^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | inobrodib (CCS1477) (CBP inhibitor, EP300 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
US FDA grants fast track status for CellCentric’s inobrodib
Published date:
06/14/2023
Excerpt:
The US Food and Drug Administration (FDA) has granted fast track designation for CellCentric’s inobrodib (CCS1477) to treat relapsed or refractory multiple myeloma patients.
